ライフサイエンスコーパス: mucormycosis

1 of the order Mucorales (the fungi that cause mucormycosis).

2 the use of statins as adjunctive therapy in mucormycosis.

3 available serum iron predisposes the host to mucormycosis.

4 tion by endosymbionts in the pathogenesis of mucormycosis.

5 available serum iron predisposes the host to mucormycosis.

6 o enhanced the host inflammatory response to mucormycosis.

7 US FDA, is a highly effective treatment for mucormycosis.

8 es predispose to certain infections, such as mucormycosis.

9 ressors can be a vehicle for transmission of mucormycosis.

10 tatins on Rhizopus oryzae, a common cause of mucormycosis.

11 the treatment of invasive aspergillosis and mucormycosis.

12 atients, who have increased GRP78 levels, to mucormycosis.

13 nvade host cells and protected DKA mice from mucormycosis.

14 Angioinvasion is a hallmark of mucormycosis.

15 eutic target for prevention and treatment of mucormycosis.

16 a diabetic ketoacidotic (DKA) mouse model of mucormycosis.

17 puted tomographic (CT) scan of patients with mucormycosis.

18 y CotH as a promising therapeutic target for mucormycosis.

19 azole monotherapy, in the cutaneous model of mucormycosis.

20 a) and a nonlethal murine model of cutaneous mucormycosis.

21 ivo in 2 phylogenetically distinct models of mucormycosis.

22 ed virulence in both fly and mouse models of mucormycosis.

23 orales species most commonly associated with mucormycosis.

24 s more often been used as a synonym only for mucormycosis.

25 so reviews the key advances against invasive mucormycosis.

26 rove the rate of early diagnosis of invasive mucormycosis.

27 or allogeneic HSCT recipients suffering from mucormycosis.

28 demiology and the clinical manifestations of mucormycosis.

29 t highly aggressive, mold infections such as mucormycosis.

30 and its subsequent impact on the outcome of mucormycosis.

31 as a strategy to improve outcomes of deadly mucormycosis.

32 ic immune serum protected mice with DKA from mucormycosis.

33 mples from 10 patients diagnosed with proven mucormycosis (2-9 samples per patient) were analyzed.

34 Of 29 cases of mucormycosis, 27 had tissue samples available for PCR an

35 d with improved survival in the fly model of mucormycosis (65% vs 57% posaconazole alone) and with si

36 Mucormycosis also remains a threat in patients with diab

37 We report a cluster of cases of cutaneous mucormycosis among Joplin tornado survivors that were as

38 investigated a cluster of cases of cutaneous mucormycosis among persons injured during the May 22, 20

39 Rhizopus oryzae is the most common cause of mucormycosis, an angioinvasive fungal infection that cau

40 toacidosis (DKA) are uniquely predisposed to mucormycosis, an angioinvasive fungal infection with hig

41 One such example is the increase of mucormycosis, an invasive infection caused by filamentou

42 ed after mobilization, one from disseminated mucormycosis and another from active lupus after postpon

43 and safety of isavuconazole for treatment of mucormycosis and compared its efficacy with amphotericin

44 useful for confirmation of the diagnosis of mucormycosis and for further characterization of the inf

45 Isavuconazole can be used for treatment of mucormycosis and is well tolerated.

46 nique susceptibility of patients with DKA to mucormycosis and provide a foundation for the developmen

47 e were presumptively identified as agents of mucormycosis and referred to the Mycology Reference Labo

48 Understanding the pathogenesis of mucormycosis and the host response to invading hyphae ul

49 owever, given the human and economic cost of mucormycosis and the need for rapid diagnosis to initiat

50 f available iron are uniquely susceptible to mucormycosis and these infections are highly angioinvasi

51 eiterates the reasons why the classic names "mucormycosis" and "entomophthoramycosis" are more approp

52 alert the hematologist to the possibility of mucormycosis, and aggressive and timely treatment approa

53 nocandins, their synergy in murine models of mucormycosis, and observational clinical data that are c

54 nd pitfalls in designing clinical studies of mucormycosis are discussed in this article.

55 New strategies to prevent and treat mucormycosis are urgently needed.

56 minimize breakthrough infection or relapsing mucormycosis associated with inadequate blood concentrat

57 ll transplant patients diagnosed with proven mucormycosis between 2001 and 2009 at Brigham and Women'

58 acidosis and became extremely susceptible to mucormycosis, but not aspergillosis, while sodium bicarb

59 Based on anatomic localization, mucormycosis can be classified as one of 6 forms: (1) rh

60 Mucormycosis cases treated with isavuconazole as primary

61 We report an invasive mucormycosis caused by Actinomucor elegans in a patient

62 e in only 1 patient with proven disseminated mucormycosis caused by Lichtheimia species.

63 2 clinicopathologically different diseases, mucormycosis caused by members of Mucorales and entomoph

64 Mucormycosis causes mortality in at least 50% of cases d

65 Invasive mucormycosis comprises a group of uncommon but emerging

66 abetic ketoacidotic or neutropenic mice with mucormycosis, deferasirox significantly improved surviva

67 of 10 patients between 68 and 3 days before mucormycosis diagnosis was confirmed by histopathologica

68 first published report of a clinical case of mucormycosis due to M. velutinosus, as well as a rare ca

69 l transplantation who developed disseminated mucormycosis due to Rhizomucor pusillus/R. miehei involv

70 Our results dissect the pathogenesis of mucormycosis during ketoacidosis and reinforce the impor

71 We exhaustively reviewed all the cases of mucormycosis (European Organisation for Research and Tre

72 h DKA, which have enhanced susceptibility to mucormycosis, exhibited increased expression of GRP78 in

73 Mucormycosis has emerged as an important opportunistic i

74 Mucormycosis has emerged as the third most common invasi

75 gic malignancy patients who develop invasive mucormycosis have not significantly improved over the pa

76 species of Mucorales for early diagnosis of mucormycosis in at-risk patients.

77 fungal pathogen capable of causing invasive mucormycosis in humans.

78 ropriate first-line therapeutic strategy for mucormycosis in organ and stem cell transplant recipient

79 d rhizoxin contribute to the pathogenesis of mucormycosis in the models studied.

80 Laboratory assessment for mucormycosis includes the conventional methods of direct

81 Because angioinvasion is a hallmark of mucormycosis infections, we sought to define the endothe

82 Mucormycosis is a deadly invasive fungal infection whose

83 Mucormycosis is a destructive invasive mold infection af

84 Mucormycosis is a devastating disease and can occur in p

85 Mucormycosis is a devastating invasive fungal disease wh

86 Mucormycosis is a fungal infection caused by environment

87 Mucormycosis is a fungal infection of the sinuses, brain

88 Mucormycosis is a life-threatening infection caused by M

89 Mucormycosis is a life-threatening infection that occurs

90 Mucormycosis is a severe emerging invasive fungal infect

91 Mucormycosis is an emerging angioinvasive infection caus

92 Mucormycosis is an uncommon invasive fungal disease with

93 Mucormycosis is difficult to diagnose.

94 Early diagnosis of invasive mucormycosis is important for timely therapeutic interve

95 Invasive wound mucormycosis (IWM) is associated with an extremely poor

96 ve aspergillosis (Aspergillus fumigatus) and mucormycosis (Lichtheimia corymbifera) murine models tha

97 Mucormycosis localization remained the only independent

98 losis and other mycoses, including agents of mucormycosis may also be transmitted from infected donor

99 mine how pharmacological aspects of treating mucormycosis may differ from those of the more commonly

100 chitin concentrations), and in vivo, using 2 mucormycosis models: an invertebrate model (Drosophila)

101 Mucormycosis most often occurs late, >3 months after tra

102 mandatory to identify healthcare-associated mucormycosis, notably in neonatology, hematological, and

103 Mucormycosis now represents a major threat in transplant

104 Data on mucormycosis obtained in France between 2005 and 2007 fr

105 with an important role for these proteins in mucormycosis pathogenesis.

106 Pulmonary mucormycosis (PM) is a life-threatening fungal infection

107 22, 2008, to June 21, 2013, 37 patients with mucormycosis received isavuconazole for a median of 84 d

108 s used by the most common etiologic agent of mucormycosis, Rhizopus oryzae.

109 Rhino-orbitocerebral mucormycosis (ROCM) caused by more common zygomycetes (e

110 We report the first case of invasive mucormycosis secondary to Actinomucor elegans infection.

111 imary as well as salvage therapy of invasive mucormycosis showed efficacy with isavuconazole that was

112 s of malaria, cysticercosis, histoplasmosis, mucormycosis, subacute sclerosing panencephalitis, and A

113 early recognition and treatment of invasive mucormycosis syndromes, as well as individualized approa

114 an accurate and rapid diagnosis of invasive mucormycosis to guide the timely initiation of amphoteri

115 oacidosis (DKA), are uniquely susceptible to mucormycosis, we sought to define the role of iron and g

116 ngal disease caused by rare fungi, including mucormycosis, were recruited from 34 centres worldwide.

117 y shows the diverse clinical presentation of mucormycosis with a high prevalence of primary skin infe

118 irox therapy to improve the poor outcomes of mucormycosis with current therapy.

119 The high mortality rate of mucormycosis with currently available monotherapy, parti

120 Isavuconazole showed activity against mucormycosis with efficacy similar to amphotericin B.

121 of Rhizopus oryzae, the most common cause of mucormycosis, with reduced CotH expression was impaired